Zulresso (brexanolone) has obtained an expanded indication to treat postpartum depression (PPD) in patients who are at least 15 years old.

• In 2019, the FDA approved Zulresso to treat PPD in adults. The drug is administered via intravenous infusion under the supervision of a qualified healthcare professional.
• A full course of treatment requires 60 hours and follows a recommended dosing schedule of:
  • 0 to 4 hours: Initiate with a dosage of 30mcg/kg of the patient’s weight per hour.
  • 4 to 24 hours: Increase dosage to 60mcg/kg/hour.
  • 24 to 52 hours: Increase dosage to 90mcg/kg/hour (or consider a dosage of 60mcg/kg/hour for individuals unable to tolerate 90mcg/kg/hour).
  • 52 to 56 hours: Decrease dosage to 60mcg/kg/hour.
  • 56 to 60 hours: Decrease dosage to 30mcg/kg/hour.